The potentials of nanotechnology-based drug delivery system for treatment of ovarian cancer

被引:17
作者
Gidwani, Bina [1 ]
Vyas, Amber [1 ]
机构
[1] Pt Ravi Shankar Shukla Univ, Univ Inst Pharm, Raipur, CG, India
关键词
chemotherapy; delivery system; nanotechnology; ovarian cancer; SOLID LIPID NANOPARTICLES; PACLITAXEL; FORMULATION; PHARMACOKINETICS; CHEMOTHERAPY; DOXORUBICIN; MANAGEMENT; CARCINOMA; NIOSOMES; TOXICITY;
D O I
10.3109/21691401.2013.853179
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Ovarian cancer is one of the leading causes for death of women. Every year the percentage of mortality rate is increasing day by day. Various chemotherapeutic agents are used to increase the survival rate of patients with ovarian cancer, but the available conventional dosage forms/marketed preparations are associated with several limitations. The use of nanotechnology in drug delivery contributes to their small size (10-100 nm), which improves the circulation and enables superior accumulation of therapeutic drugs at the tumor sites. In future, the use of nanotechnology will enable passive targeting and further improvements can be made using targeting moieties.
引用
收藏
页码:291 / 297
页数:7
相关论文
共 59 条
  • [21] Nanoparticle-assisted combination therapies for effective cancer treatment
    Hu, Che-Ming Jack
    Aryal, Santosh
    Zhang, Liangfang
    [J]. THERAPEUTIC DELIVERY, 2010, 1 (02) : 323 - 334
  • [22] Caprolactonic poloxamer analog: PEG-PCL-PEG
    Hwang, MJ
    Suh, JM
    Bae, YH
    Kim, SW
    Jeong, B
    [J]. BIOMACROMOLECULES, 2005, 6 (02) : 885 - 890
  • [23] Cancer statistics, 2005
    Jemal, A
    Murray, T
    Ward, E
    Samuels, A
    Tiwari, RC
    Ghafoor, A
    Feuer, EJ
    Thun, MJ
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2005, 55 (01) : 10 - 30
  • [24] Medium scale production of solid lipid nanoparticles (SLN) by high pressure homogenization
    Jenning, V
    Lippacher, A
    Gohla, SH
    [J]. JOURNAL OF MICROENCAPSULATION, 2002, 19 (01) : 1 - 10
  • [25] Block copolymer micelles for drug delivery: design, characterization and biological significance
    Kataoka, K
    Harada, A
    Nagasaki, Y
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2001, 47 (01) : 113 - 131
  • [26] Kim HK, 2002, MACROMOL RAPID COMM, V23, P26, DOI 10.1002/1521-3927(20020101)23:1<26::AID-MARC26>3.3.CO
  • [27] 2-9
  • [28] In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy
    Kim, SC
    Kim, DW
    Shim, YH
    Bang, JS
    Oh, HS
    Kim, SW
    Seo, MH
    [J]. JOURNAL OF CONTROLLED RELEASE, 2001, 72 (1-3) : 191 - 202
  • [29] Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens
    Kloover, JS
    den Bakker, MA
    Gelderblom, H
    van Meerbeeck, JP
    [J]. BRITISH JOURNAL OF CANCER, 2004, 90 (02) : 304 - 305
  • [30] Poly[lactic-co-(glycolic acid)]-Grafted Hyaluronic Acid Copolymer Micelle Nanoparticles for Target-Specific Delivery of Doxorubicin
    Lee, Hyukjin
    Ahn, Cheol-Hee
    Park, Tae Gwan
    [J]. MACROMOLECULAR BIOSCIENCE, 2009, 9 (04) : 336 - 342